Aravive, Inc. (ARAV): Price and Financial Metrics

Aravive, Inc. (ARAV): $0.04

0.01 (-13.39%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

C

Add ARAV to Watchlist
Sign Up

Industry: Biotech

Industry

NR

Ranked

#144 of 393

in industry

ARAV Price/Volume Stats

Current price $0.04 52-week high $2.46
Prev. close $0.05 52-week low $0.04
Day low $0.04 Volume 4,040,000
Day high $0.05 Avg. volume 4,251,645
50-day MA $0.12 Dividend yield N/A
200-day MA $0.70 Market Cap 2.95M

ARAV Stock Price Chart Interactive Chart >


Aravive, Inc. (ARAV) Company Bio


Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases. Its lead product candidate is AVB-500, a decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase Ib/II clinical trial for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, triple negative breast cancer, acute myeloid leukemia, and pancreatic cancer. The company has a strategic collaboration agreement with WuXi Biologics to develop novel high-affinity bispecific antibodies targeting cancer and fibrosis. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. is headquartered in Houston, Texas.


ARAV Latest News Stream


Event/Time News Detail
Loading, please wait...

ARAV Latest Social Stream


Loading social stream, please wait...

View Full ARAV Social Stream

ARAV Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year -69.54%
3-year -98.45%
5-year -99.69%
YTD -67.66%
2023 -90.63%
2022 -39.73%
2021 -61.17%
2020 -58.74%
2019 288.35%

Continue Researching ARAV

Want to see what other sources are saying about Aravive Inc's financials and stock price? Try the links below:

Aravive Inc (ARAV) Stock Price | Nasdaq
Aravive Inc (ARAV) Stock Quote, History and News - Yahoo Finance
Aravive Inc (ARAV) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!